0000000001216639
AUTHOR
M. Di Girolamo
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.
BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…
Ribosome Heterogeneity in Plant and Animal Organisms. Its Relationship to Ribosomal Ambiguity and to Ribosome Evolution
Abstract The data presented and discussed in this report summarize evidence showing that ribosomes isolated from several eucaryotic (plant and animal) organisms exhibit ample variations of the composition of their protein moiety and that the degree of dissimilarity correlates with the degree of taxonomic kinship of the organisms from which the ribosomes were derived. They also provide evidence that (a) the 80-S ribosomes isolated from the cytoplasmic matrix of higher plants and yeast and the 70-S ribosomes derived from both chloroplasts and mitochondria are endowed with highly dissimilar protein complements, (b) the organellar (67-S) ribosomes derived from the chloroplasts of more or less d…